# Bone Biologics (BBLG) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BBLG
## Company Profile
- Ticker: BBLG
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.558 USD
- Market cap: 2279980.2 USD
- Last updated: 2026-09-03
## Business Overview
Bone Biologics is a biotechnology company focused on bone regeneration and spinal fusion support products. Its story centers on using biologic materials to improve orthopedic healing.
## Why The Stock Is Moving

The latest company update was “Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference”. BBLG changed 1.38% and closed at $0.5580 on Sep 3, 2026, indicating a relatively limited closing-price reaction to this conference / presentation update.

## Geographic Base

Bone Biologics is headquartered in the United States and listed on NASDAQ. It sits in regenerative medicine and orthopedic biotechnology.

## Business Model

The company depends on clinical and preclinical progress, product development, and the ability to create a differentiated bone-growth platform. Investors usually watch data, regulatory steps, and capital runway.

## Landscape Position

Bone Biologics occupies a small orthopedic-regeneration niche within biotech. The stock is sensitive to whether its biologic platform can translate into meaningful surgical use.

## Future Catalysts

- Bone Biologics’ catalysts are NELL-1 / spine-regeneration work and any update that shows the platform can still progress clinically. The company remains highly dependent on proof of concept.

## Recent News
- 2026-09-03 12:30 EST — [Bone Biologics to Participate in the  H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/BBLG/bone-biologics-to-participate-in-the-h-c-wainwright-28th-annual-global-investmen-5815f866) — Source: Bone Biologics
- 2026-08-12 12:00 EST — [Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1](https://biopharmsignal.com/news/BBLG/bone-biologics-achieves-32-month-validated-shelf-life-for-rhnell-1-0685dae2) — Source: Bone Biologics
- 2026-07-23 12:00 EST — [Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities](https://biopharmsignal.com/news/BBLG/bone-biologics-issues-mid-year-shareholder-update-highlighting-progress-across-2-9130fb80) — Source: Bone Biologics
- 2026-07-08 00:00 EST — [Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BBLG/bone-biologics-announces-up-to-9-0-million-private-placement-priced-at-the-marke-7231c29e) — Source: Bone Biologics
- 2026-05-19 12:00 EST — [Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1](https://biopharmsignal.com/news/BBLG/bone-biologics-achieves-29-month-validated-shelf-life-for-rhnell-1-287ecf34) — Source: Bone Biologics